Compare Natera Inc. Common Stock (NTRA) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Teradyne, Inc. — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Teradyne, Inc. trades at $349.91 (market cap $59.45B). The key difference: Natera Inc. Common Stock and Teradyne, Inc. are close in size by market cap, and Teradyne, Inc. pays a 0.14% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Teradyne, Inc. for 37 Days on average.
| NTRA | TER | |
|---|---|---|
Market Cap | $57.03B | $59.45B |
Volume | 1,131,157 | 2,735,541 |
Sector | Health | Technology |
52-Week High | $425.64 | $483.84 |
52-Week Low | $179.42 | $138.09 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $56.18B | $59.20B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Teradyne (TER) trades at $359.44, down 6.36% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a 25.77% net income margin and consistent earnings beats in recent quarters. Recent news highlights expansion in AI-driven test equipment, including the Magnum E2 and Iris 100 platforms, targeting growth in semiconductor and data center markets. Analyst consensus remains bullish with a $461.50 price target, though technical indicators suggest near-term caution.
Outlook is positive due to robust profitability and AI-related demand, but risks include competitive pressures and market volatility. The stock offers growth potential if execution aligns with analyst expectations, though investors should monitor earnings consistency and industry trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
